Saudi FDA To Cut Drug Approval Time With Abridged Reviews
This article was originally published in SRA
The Saudi Food and Drug Authority is planning to introduce a system of abridged regulatory reviews for drugs that could cut the approval timeline by around 40% and make it easier for companies to both bring their products to Saudi Arabia and produce them locally. In another move, the agency is creating a new department to assess benefit-risk profiles and a new risk assessment model.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.